Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy;Prevalencia y riesgo potencial de interacciones medicamentosas mediadas por el citocromo P450 en pacientes ancianos polimedicados hospitalizados

Annals of Pharmacotherapy

Volumn 47, Issue 3, 2013, Pages 324-332

  Doan, Julie ^a   Zakrzewski Jakubiak, Hubert ^a   Roy, Julie ^a   Turgeon, Jacques ^b   Tannenbaum, Cara ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

AGE; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DRUG INTERACTION; DRUG INTERACTION; FEMALE; GENDER; GERIATRIC PATIENT; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; PATIENT MONITORING; PHARMACIST; POLYPHARMACY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HOSPITALIZATION; HOSPITALS, COMMUNITY; HUMANS; MALE; POLYPHARMACY; PREVALENCE; PROSPECTIVE STUDIES; RISK;

EID: 84875192880     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R621     Document Type: Article

References (28)

1. Huang SM, Strong JM, Zhang L, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters and the guidance process. J Clin Pharmacol 2008;48:662-70.
2. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270: 414-23.
3. Shapiro LE, Shear NH. Drug interactions: proteins, pumps, and P-450s. J Am Acad Dermatol 2002;47:467-84.
4. Mann HJ. Drug-associated disease: cytochrome P450 interactions. Crit Care Clin 2006;22:329-45.
5. Zhang L, Xu N, Xiao S, et al. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease. J Clin Pharmacol 2012;52:79S-90S.
6. International Conference on Harmonisation. E7(R1): studies in support of special populations: geriatrics. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E7/Q_As/E7R1_Final_Concept_Paper.pdf (accessed 2012 Sept 24).
7. Abarca J, Colon LR, Wang VS, et al. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm 2006;12:383-9.
8. Sweidan M, Reeve JF, Brien JA, et al. Quality of drug interaction alerts in prescribing and dispensing software. Med J Aust 2009;190:251-4.
9. Lapane KL, Waring ME, Schneider KL, et al. A mixed method study of the merits of e-prescribing drug alerts in primary care. J Gen Intern Med 2008;23:442-6.
10. Magnus D, Rodgers S, Avery AJ. GPs' views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther 2002;27:377-82.
11. Zakrzewski-Jakubiak H, Doan J, Lamoureux P, Singh D, Turgeon J, Tannenbaum C. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of a new cytochrome p450-based software. Am J Geriatr Pharmacother 2011;9:461-70. doi: 10.1016/j.amjopharm.2011.09.006.
12. Turgeon J. InterMED-Rx. Harmony and optimal therapy in the use of medication. http://ws-ddi.intermed-rx.ca/(accessed 2012 Jul 16).
13. US Food and Drug Administration. Guidance for industry on drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations, February 2012. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf (accessed 2012 Jun 8).
14. European Medicines Agency. Committee for medicinal products for human use. Guideline on the investigation of bioequivalence. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070 039.pdf (accessed 2011 Jun 8).
15. Birkett DJ. Generics-equal or not? Australian Prescriber 2003;26(4):85-7.
16. The Pharmaceutical Press. Stockley's drug interactions. www.medicines complete.com/mc/stockley/current/(accessed 2010 Sept 1).
17. Micromedex. Thomson Reuters. www.thomsonhc.com/home/dispatch (accessed 2010 Sept 1).
18. Hansten PD, Horn JR, eds. Drug interactions analysis and management. St. Louis, MO: Wolters Kluwer Health, Inc., 2010.
19. Fleiss JL, Levin B, Cho Paik M, eds. Statistical methods for rates and proportions. 3rd ed. New York: John Wiley & Sons, 2003.
20. Davies SJ, Eayrs S, Pratt P, Lennard MS. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol 2004;57: 464-72.
21. Mulder H, Heerdink ER, van Iersel EE, Wilmink FW, Egberts ACG. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study. Ann Pharmacother 2007;41:408-13. doi: 10.1345/aph.1H482
22. Zhou SF. Polymorphism of human cytochrome P4502D6 and its clinical significance: part II. Clin Pharmacokinet 2009;48:761-804. doi: 10.2165/11318070-000000000-00000
23. Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 2011;9:364-77. doi: 10.1016/j.amjopharm.2011.10.004
24. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007;370:185-91.
25. Hines LE, Malone DC, Murphy JE. Recommendations for generating, evaluating, and implementing drug-drug interaction evidence. Pharmacotherapy 2012;32:304-13. doi: 10.1002/j.1875-9114.2012.01024
26. Gallagher P, Barry P, O'Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther 2007;32:113-21.
27. McKibbon KA, Lokker C, Handler SM, et al. The effectiveness of integrated health information technologies across the phases of medication management: a systematic review of randomized controlled trials. J Am Med Inform Assoc 2012;19:22-30.
28. Calabretto J-P, Warren J, Bird L. Pharmacy decision support: where is it? A systematic literature review. Int J Pharm Pract 2005;13:157-64. doi: 10.1211/ijpp.13.3.0001